🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — May 13, 2026

The 50 filings for USA Dow Jones 30 stream, dominated by 13F-HR disclosures from institutions managing trillions in AUM, reveal overwhelming conviction in DJIA mega-cap tech leaders like Apple (top holding in 20+ filings, e.g., First Citizens $153B, Visionary $101M), Amazon, Alphabet, Nvidia, and Microsoft, with select QoQ share increases (e.g., Alesco +5.4% AAPL, +2.3% AMZN). Operational 10-Q/8-K filings show mixed Q1 2026 results across non-DJIA names: robust growth in energy (NGS rental rev +21% YoY, EBITDA guide to $92.5-97.5M), airlines (ALGT Sun Country acquisition, $140M synergies), and tech (Cisco rev +12% YoY to $15.8B, FY guide $62.8-63B; Identiv +40.7% rev), but persistent cash burn and losses in biotechs (Acrivon op ex down 8% YoY but cash use +5%; Aquestive cash to $110M). Capital allocation trends favor returns: NGS div +36% to $0.15, NB Bancorp completed buybacks of 16% shares since IPO at $19.25 avg, Cisco $0.42 div. Forward guidance largely raised/reaffirmed (5/7 cases), signaling resilience amid margin pressures (e.g., Cisco gross margin -200bps to 63.6%). Portfolio-level patterns highlight tech overweight (60%+ top holdings), energy/mining adds (Kopernik +4.2% NovaGold), and fixed income ETF tilts for defense.

12 high priority 38 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 13, 2026

Across 50 SEC filings for May 13, 2026, key themes include robust SPAC activity with multiple IPOs (Starlink AI, West Enclave) raising $200M+ and extensions (Aquaron, GP-Act III), signaling renewed M&A appetite in a potentially frothy market. Q1 2026 10-Qs reveal polarized performance: 14/22 reporting companies posted YoY revenue growth averaging 85% (outliers like SS Innovations +117%, SOLV Energy +66%), but 18/22 widened net losses amid SG&A surges (e.g., SOLV non-cash comp +8,300%), highlighting growth-at-all-costs in small caps/biotechs. Annual meetings (10+ filings) overwhelmingly passed director elections, say-on-pay, and auditor ratifications with >90% support, indicating stable governance. Biotech/health firms (Anteris, Azitra, Zenas) advanced trials with capital raises extending runways to 2029, while consumer/retail showed resilience (National Vision +6.6% rev, +4.4% comp sales). Capital allocation leans shareholder-friendly: Expensify $25M tender, News Corp $1B buyback authorization. Portfolio-level: Margin expansion rare (National Vision +150bps adj op margin), but cash burns average $4M/Q in loss-makers; forward catalysts cluster in H2 2026 trials/data readouts. Implications: Favor disciplined growers like National Vision/Cigna; monitor SPAC redemptions and biotech burn rates for downside risks.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 13, 2026

The 50 filings, dominated by 13F-HR reports from institutions managing trillions in AUM, reveal unwavering conviction in S&P 500 Consumer Discretionary mega-caps like Apple (e.g., First Citizens $153.7B position, Martingale $55.4M), Amazon ($62.6B First Citizens, $140M NewEdge), and Alphabet ($233M NewEdge Cl A), with stable Q1 2026 portfolios across 30+ filers signaling no major rotations out of consumer tech/retail leaders. Retail operators show sales headwinds (Fossil -3.6% YoY to $224.8M, Lulus -10% to $57.5M) but resilient margins (Fossil gross 59.9%, op margin 5.4% swing to profit) and cost discipline (Fossil SG&A -9.9%, Lulus inventory -17%), narrowing losses amid FY guidance for positive EBITDA (Lulus) and 3-5% adj margins (Fossil). Key catalysts include FedEx Freight spin-off (record May 15, trading June 1 2026, 80.1% dividend distribution unlocking $4.1B value) and Las Vegas Sands $1B debt refi (higher 5.3-5.65% rates vs 3.5%). Mixed financials/funds (e.g., Bogota NI -3.4% YoY, Finward +393%) hold consumer exposure, while crypto ETFs (Canary suite) post sharp NAV declines (XRP -18% QoQ, Solana -40.5%) on unrealized depreciation. No notable insider trades or buybacks; capital allocation leans to distributions (e.g., New Mountain $8.9M up YoY) and debt management. Portfolio-level trend: Steady institutional overweight in consumer discretionary amid ops challenges implies defensive positioning for H2 2026 recovery.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 13, 2026

Across 50 filings in the S&P 500 Healthcare intelligence stream dated May 13, 2026, direct operational updates from biotechs and providers reveal mixed Q1 2026 results with 7/9 healthcare firms showing narrowed net losses YoY (avg improvement ~40%) amid revenue ramps in select names like Precigen (+$21.9M YoY from near-zero on PAPZIMEOS launch) and Precision Optics (+108% YoY revenues), though cash burns persist and some revenues declined (e.g., CareView -2% YoY). 35+ 13F-HR filings from institutions like Merck, J&J, and others disclose stable holdings in healthcare/biotechs (e.g., Merck's $117M Moderna, J&J's $258M Protagonist), signaling sustained conviction without reported changes QoQ. Positive shareholder meetings at Vertex (97% avg director approval), Elevance Health, and others contrast proxy risks at Pacira; forward catalysts cluster in H2 2026 (PDUFAs, ASCO data). Capital allocation lean: dividends steady (e.g., Tri-County +12% YoY), no major buybacks noted in health filers. Portfolio-level trend: biotechs prioritizing commercialization (payer coverage expansions, J-codes) over R&D (avg -25% YoY spend), positioning for 2027 revenue inflection but risking near-term dilution.

19 high priority 31 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 13, 2026

Across 14 DEF 14A proxy statements filed around May 13, 2026, for US companies primarily holding annual meetings in June 2026, dominant themes include routine director elections (12/14 filings), advisory votes on executive compensation (9/14), auditor ratifications (8/14), and equity incentive plan expansions (e.g., BOX +7.2M shares, Oxford +750K shares, HealthEquity amended EIP), signaling expectations of future growth and talent retention amid strong governance emphasis (e.g., BOX 7/8 independent directors, Kroger all but CEO/Chair independent). Period-over-period trends are sparse but revealing: Kroger reported nearly doubled identical sales ex-fuel and 9% EPS growth in 2025 with eCommerce profitability at $16B, planning 30% new store growth in 2026 (positive outlier), while Bunker Hill Mining saw net losses widen sharply to $(90.4M) in 2025 from $(29.2M) in 2024 despite 14% YoY PEO compensation increase and TSR up to $140 (mixed signal). Other highlights include M3-Brigade's high-materiality SPAC merger with $500M PIPE (post-close PIPE owns 55%), AudioEye's 99% Say-on-Pay approval with 100% equity director comp, and leadership transitions (e.g., Perma-Pipe 3 resignations, Oxford director retirement at 72). Portfolio-level patterns show tech/cloud firms (BOX, SentinelOne, Marvell) prioritizing board stability and equity pools, retail (Kroger, Oxford) highlighting performance/governance, and small-caps/mining (Bunker Hill, SKYX) disclosing comp details amid volatility. Market implications favor monitoring June votes for comp/equity approvals as sentiment gauges, with bullish retail catalysts offsetting dilution risks in micro-caps like Classover (2.5B Class B authorization). No widespread insider selling noted, but equity-heavy comp (e.g., AudioEye RSU holdings up to 102K vested) indicates alignment.

14 high priority 14 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 13, 2026

The IPO Pipeline stream shows two key filings on May 13, 2026: USA Rare Earth (USAR) S-4 for a strategic merger with Texas Mineral Resources Corp. (TMRC), carrying positive sentiment and high materiality (9/10), and Nauticus Robotics S-1 for resale of up to 103.7M shares under a $250M facility, mixed sentiment (8/10 materiality) amid dilution risks. No direct YoY/QoQ financial trends available in these registration statements, but USAR's merger implies consolidation potential in rare earths with a fixed 3.82M share pool exchange. Nauticus demonstrates recent positive trend in Nasdaq compliance (regained Dec 19, 2025 after Oct 2025 deficiencies) but faces ongoing monitoring. Critical development: USAR-TMRC Q3 2026 closing catalyst post TMRC vote, offering de-SPAC-like path to public markets for TMRC. Portfolio-level pattern: 1/2 filings (50%) leverage mergers/S-1s for capital access/public listing in emerging sectors, highlighting small-cap reliance on dilutive/strategic structures amid regulatory hurdles.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — May 13, 2026

Across 50 pre-analyzed US SEC and global filings for May 13, 2026, mixed sentiment dominates (70% of filings), with stark contrasts between revenue growth in industrials/tech (e.g., Astronics +12% YoY sales, AmpliTech +49% revenue) and deepening losses/cash burns in biotechs/pharma (Semnur op ex +588% YoY) and crypto ETFs (NAV drops 18-40% QoQ amid unrealized depreciation). Period-over-period trends reveal portfolio-level margin compression averaging -100 bps in financials/REITs (LIC Housing NIM -5 bps, Bogota non-int inc -64% YoY), offset by capital returns like Cybertech's 2.73% buyback at ₹170/share and LIC's 500% dividend. Critical developments include Radhagobind's ongoing CIRP insolvency (8th COC meeting May 15), HF Sinclair CFO termination, and Nuvve's dilutive warrant exchange needing approval by July 27; crypto ETFs show crypto price sensitivity with Canary XRP/Solana NAV -18%/-40% QoQ. Sector themes highlight biotech cost-cutting (R&D -30-70% YoY in Spruce/Dermata) amid cash raises, while buybacks/dividends signal conviction in software/financials. Implications: Near-term alpha in buyback catalysts and turnarounds, but watch distress in microcaps/insolvencies for downside risks.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 13, 2026

Across 50 Q1 2026 10-Q filings, sentiment is predominantly mixed (38/50), with 6 negative and revenue growth averaging +25% YoY in outperformers like STAAR Surgical (+120%) and Astronics (+12%), but widespread margin compression (-150 bps avg in 12/20 operating cos) and cash burn in biotechs/pharma (e.g., Semnur op ex +588% YoY). Banks/insurers show resilience with net income +50% YoY avg (e.g., Avidbank +66%, UTG +81%), while crypto ETFs suffer massive unrealized depreciation (avg -25% NAV QoQ, e.g., Canary XRP -18%). Capital allocation leans conservative with buybacks/dividends in banks (Embassy repurchased $3M shares) amid rising debt in 15 cos (avg +10% QoQ). Portfolio trend: 22/50 cos improved op cash flow YoY, signaling working capital stabilization, but 18/50 deepened losses/stockholders' deficits. Key implication: Rotate to banks/turnarounds (Snail +operating income swing), avoid high-burn biotechs/crypto; watch leverage in trusts/REITs. No major guidance changes, but B&G Foods flags covenant risks.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 13, 2026

Three Nasdaq Capital Market small-cap companies disclosed critical listing compliance failures in 8-K filings around May 13, 2026, signaling heightened delisting risks amid governance lapses and share price weakness. CEA Industries violated Rule 5620(a) by failing to hold an annual shareholders' meeting within 12 months of FYE April 30, 2026, with a 45-day compliance plan deadline to June 22 and potential 180-day extension to October 27. Intrusion Inc. breached Rule 5550(a)(2) with closing bid prices below $1.00 for 30 consecutive trading days from March 25 to May 6, 2026, entering a 180-day grace period to November 3 with possible further extension via reverse split plan. Reviva Pharmaceuticals faces immediate delisting after missing its final bid price compliance deadline on May 11, with trading suspension at Nasdaq open on May 14, 2026, and shift to OTCQB under RVPH. Overarching themes include persistent QoQ share price declines (e.g., 30-day streak below $1), governance deterioration, and negative sentiment (all filings scored negative, avg materiality 9.3/10), with no bullish period-over-period trends evident. Portfolio-level implications: Increased volatility, liquidity evaporation, and short opportunities in Nasdaq small caps; no insider activity, capital allocation, or financial ratio improvements noted across filings.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 13, 2026

Across 34 filings in the USA Corporate Distress & Bankruptcy stream, a mixed landscape emerges with 4 prominent Nasdaq compliance failures signaling acute distress (delisting risks for CEA Industries, Intrusion, Reviva, Ryvyl), offset by robust revenue growth in biotechs and energy firms (e.g., Aquestive +66% YoY, Eos +445% YoY, Allogene R&D expenses -36% YoY). Period-over-period trends show revenue expansion in 7/34 companies (avg +100% YoY where reported) but persistent losses narrowing in 4 cases, alongside heavy dilution from equity offerings/ATM (Nuvve 55% shares, iSpecimen, CEL-SCI) and debt refinancings (Tempus $350M notes, LVS $1B notes). Capital allocation leans toward financings (12 new facilities/offerings) and buybacks ($206M total in Prestige/ACV), with M&A/acquisitions in 5 firms indicating strategic pivots amid distress. Portfolio-level patterns highlight small-cap Nasdaq vulnerabilities (3/34 bid price/annual meeting issues) and biotech resilience (positive trials/guidance in Allogene/Aquestive/Armata), but overall sentiment skews mixed/neutral with 10/34 filings showing dilution risks. Critical implications include near-term catalysts like Nuvve stockholder vote (Jul 27) and Reviva delisting (May 14), urging monitors for liquidity crunches in distressed names.

34 high priority 34 total filings
· daily

US Executive Officer Management Changes SEC — May 13, 2026

Across 41 filings on USA Executive & Director Changes from May 13, 2026, the dominant theme is orderly leadership transitions, with 12 CEO/CFO/COO changes (e.g., HF Sinclair CFO terminated after leave, Power Solutions CEO resignation to interim CFO, Rent the Runway CEO to interim), 15+ successful annual meetings approving directors (90-99% support), comp plans, and auditors, signaling strong shareholder alignment. Financial reporters show mixed period trends: Doximity FY2026 revenue +13% YoY to $644.9M but Q4 net income -69% to $19.1M; Jack in the Box Q2 revenue -4.3% YoY, SSS -3.8%, margins -320 bps; Tango Q1 net loss +14% to $45.5M despite cash runway to 2028; Zenas Q1 net loss widened to $81M on +73% R&D. Capital allocation remains shareholder-friendly with Hanover's $700M buyback (replacing $63M remainder), Coeur's inaugural $0.02/share dividend (record May 22), and multiple LTIPs approved (e.g., MDU +6.5M shares). Positive sentiments dominate (22/41 positive, 10 neutral), with biotech/pharma showing clinical catalysts (Zenas BLA Q2 2026) amid leadership refreshes, implying sector rotation opportunities but watch CFO turnover (6 cases) for finance risks.

41 high priority 41 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 13, 2026

Across 41 SEC filings on USA Board Room Changes from May 13, 2026, the dominant theme is high C-suite and board turnover, with 12 CEO/CFO/president departures or transitions (e.g., HF Sinclair CFO termination, Power Solutions CEO resignation, Rent the Runway CEO step-down) amid neutral-to-negative sentiment, signaling potential instability in energy, pharma, and tech sectors. Annual shareholder meetings (15 filings) overwhelmingly passed director elections, auditor ratifications, and equity plans with 90-99% support (e.g., Vertex 94-99%, MDU >90%), reinforcing governance stability. Period-over-period trends show mixed financials: revenue growth in Doximity (+13% FY2026 YoY to $644.9M) and cash runway extensions (Tango to 2028, Zenas to Q2 2029), but margin compression in consumer names (Jack in the Box Restaurant-Level Margin -320 bps YoY to 16.4%) and widening losses in biopharma (Tango net loss +14% to $45.5M, Zenas +141% to $81M). Capital allocation leans bullish with Hanover's $700M buyback authorization (+$637M vs prior remainder), Coeur Mining's inaugural $0.02/share dividend, and LTIP expansions (e.g., MDU +6.56M shares). Forward-looking catalysts cluster in pharma (e.g., Zenas BLA Q2 2026, Tango data readouts 2026), while leadership promotions signal continuity (e.g., Toll Brothers EVP to President). Portfolio implication: Favor stable boards with buybacks/dividends; avoid high-turnover firms until interim stability proven.

41 high priority 41 total filings
· daily

US Merger & Acquisition SEC Filings — May 13, 2026

The 15 filings reveal a vibrant SPAC ecosystem with 12/15 involving blank-check companies advancing through IPOs (West Enclave, Starlink AI), unit separations (Maywood, Inflection Point), deadline extensions (Aquaron to 2027, GP-Act III to Nov 2026, Future Vision to June 2026, SIM to July 2027), and merger amendments (Live Oak V, FG Merger II), signaling sustained M&A pursuit amid avoiding liquidations. A standout airline sector consolidation: Allegiant Travel completed its $140M-synergy acquisition of Sun Country on May 13, 2026, forming a leisure airline giant with 195 aircraft and EPS accretion in year 1, while Sun Country delisted. M3-Brigade's proxy for ReserveOne de-SPAC targets June 15 EGM with PIPE at ~$500M valuation. One termination (Iris Acquisition Corp II LOI with Freedom Metals) stands out negatively. Target A&B Aerospace (PMGC) showed strong YoY trends: 9-mo revenue +12.8% to $3.6M, 3-mo +25.5% to $1.3M, net income swing to profit. No insider trading or capital allocation shifts noted across filings; portfolio trend shows SPAC extensions preserving ~$100M+ trusts each, with forward catalysts clustered May-June 2026.

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 13, 2026

Overnight SEC filings from May 12-13, 2026, reveal a mixed Q1 2026 earnings landscape across 50 reports, with standout revenue growth in small-caps like SS Innovations (+117% YoY), SOLV Energy (+66% YoY), and ASIAFIN (+105% YoY), contrasted by declines in DarioHealth (-17% YoY), Hughes Satellite (-11% YoY), and Spectral AI (-40% YoY R&D revenue). SPAC activity surges with new IPOs (Starlink AI $100M, West Enclave $115M total), extensions (Aquaron to 2027, GP-Act III to Nov 2026), and non-redemptions boosting deal prospects. Annual meetings dominate with strong approvals (Lockheed Martin 86% quorum, Innospec 91%), signaling governance stability, while capital allocation favors buybacks (News Corp $1B program), tenders (Expensify $25M), and debt refinancings (Tempus AI $350M notes, SOLV post-IPO paydown). Biotech firms like Zenas, Anteris, and Azitra report widened losses from R&D but bolstered cash via raises ($320M Anteris, $419M Zenas), extending runways to 2029. Portfolio trends show margin expansions in National Vision (+760 bps adj op margin to 10.2%) and Regis (+improved op income despite -8% rev), but compressions elsewhere; forward catalysts cluster in H2 2026 trials/data readouts. Implications: Bullish for SPACs and growth small-caps pre-market, cautious on biotechs with burn rates, watch guidance reaffirms like Cigna's $30.35 EPS.

31 high priority 19 medium 50 total filings
· daily

Big Pharma Approvals — May 12, 2026

The FDA approval period from May 12 to May 12, 2026, featured 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other approval, representing a quiet week dominated by a single bullish signal from Big Pharma. GENENTECH INC secured a label expansion for OCRELIZUMAB (OCREVUS), categorized as a fallback/other approval, signaling moderate upside potential (strength 5/10, materiality 5/10) for the sponsor's established franchise. No dominant therapeutic area theme emerged from this single event. The highest-conviction signal is GENENTECH INC's OCRELIZUMAB label expansion, which could support sustained revenue contribution amid limited disclosure on peak sales, exclusivity, or pricing. A key risk/watch item is the lack of disclosed commercial details, warranting monitoring for post-approval uptake and competitive dynamics.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 12, 2026

Across 39 filings in the S&P 500 Technology stream (with some adjacent sectors), Q1 2026 results reveal robust revenue growth averaging +22% YoY in reporting companies (e.g., Ducommun +9%, Madison Air +33.8%, NVIDIA FY26 +65%), but mixed profitability with margin expansions in industrials (+70 bps Ducommun) offset by widening losses in biotechs (Immunome +29% YoY net loss). Institutional 13F-HR filings (13 total) show heavy concentration in tech/semiconductors (NVDA, AMD, Broadcom top holdings across Azimuth, Belvedere, Ilmarinen), signaling sustained conviction amid AI/data center tailwinds. Positive AGMs (Cadence 90-99% approvals, Atmus >95%) and capital raises (Madison IPO $2.58B net, AIM warrant exercise $3.6M) underscore shareholder alignment, while takeover tensions (Diana's 14.7% Genco stake, proxy fight June 18) add volatility. Forward guidance is optimistic where provided (Madison FY26 sales $3.75-3.85B, Immunome cash to 2028), but liquidity risks emerge in cash-burners (Imunon -45% QoQ cash). Sector themes highlight tech growth resilience vs. operational pressures in smaller names, positioning AI/semicon leaders for outperformance.

13 high priority 26 medium 39 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 12, 2026

Across 40 filings from NASDAQ-100 related entities on May 12, 2026, Q1 2026 earnings dominate with robust revenue growth in aerospace/defense (Ducommun +9% YoY), HVAC (Madison +33.8% YoY), IT services (Intellicheck +13% YoY, Intelligent Protection +15.2% YoY), and shipping (Genco EBITDA +331% YoY), but mixed profitability due to cost pressures and biotech losses widening (Immunome +29%, Imunon +3.6%). Margin expansions noted in 4/10 reporting companies (e.g., Ducommun gross +70 bps, Madison Adj EBITDA +89 bps), while cash positions declined QoQ in 7/12 cases amid inventory builds and R&D spends. Forward-looking catalysts include Madison FY2026 guidance ($3.75-3.85B sales), biotech trials (PepGen 2H 2026 data, Imunon Phase 3 2029), and AGMs (Genco/Dyadic June 18, NVIDIA June 24). Institutional 13Fs (Intel, AMD, Belvedere) show heavy tech/options exposure with no major shifts, signaling steady conviction. Shipping M&A battle (Diana 14.7% Genco stake, proxy fight) and capital raises (Madison IPO debt repay, AIM $3.6M warrants) highlight deleveraging trends. Portfolio implication: overweight aero/IT growth, monitor biotech liquidity and shipping takeover premium.

14 high priority 26 medium 40 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 12, 2026

Across 50 filings in the USA S&P 500 Financials stream, 30+ are 13F-HR disclosures from asset managers and institutions revealing overwhelming concentration in mega-cap tech (Apple, NVIDIA, Amazon topping 80% of portfolios, avg 30-43% allocation) and ETFs, signaling strong conviction in tech amid financials focus. Earnings reporters (7 high-materiality 8-Ks) show mixed Q1 2026 trends: revenue growth averaging +11% YoY in 5/7 (Ducommun +9%, Qnity +18%, Green Dot +17%, Optex flat 6-mo, BETA +5.6%), but net losses widening in growth names (BETA to $122M from $78M) and GAAP declines (Qnity NI -19%). Guidance mostly raised (Qnity FY sales $5.225-5.375B +~10%, Optex FY rev $43-45M +5-9%), with margin expansions in industrials (Ducommun +70bps, Optex +390bps). Key developments include eBay rejecting $20B GameStop bid (confident in $80B GMV standalone), Green Dot B2B-driven +109% NI amid acquisition progress, and S&P Global Mobility spin-off Investor Day. Portfolio-level: Financial institutions underweight sector peers, overweight tech (e.g., National Pension $13B+ in top tech), implying rotation risks; capital allocation lean with News Corp $1B buyback and UGI €300M notes.

6 high priority 44 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 12, 2026

The 50 filings for USA S&P 500 Consumer Staples stream reveal limited direct sector exposure, with institutional 13F-HR disclosures (22/50 filings) overwhelmingly concentrated in mega-cap tech (e.g., Apple, Nvidia, MSFT comprising 40-60% of portfolios across Circle Wealth, Channel Wealth, Sittner & Nelson, etc.), signaling broad investor preference for growth over defensive staples. Operational results from available Q1 2026 data show mixed trends: revenue growth in outliers like Qnity Electronics (+18% YoY to $1.3B, organic +17%) and New Mountain Net Lease (+11% YoY revenues), but declines in Under Armour (-1% Q4 YoY) and SideChannel (-16.8% Q2 YoY), with margin compression averaging -200-400 bps in pressured names amid cost inflation. Leadership changes dominate non-13F filings, with positive transitions (Diodes Chairman retirement after scaling revenue 10x, Standard Motor new COO) contrasting HF Sinclair's CEO/CFO separations (severance $4.7M, ongoing leave). Forward guidance includes Qnity's raised FY2026 sales ($5.225-5.375B, Adj EPS $3.80-4.14) and Under Armour's FY2027 slight revenue decline but +220-270 bps margins; annual meetings (Pangaea, Clearwater, Steele Bancorp) passed all items with strong majorities. Capital allocation leans conservative (e.g., no debt at Verde Clean Fuels with $54M cash), while M&A progress (Apellis HSR clearance for $41/share + CVR tender) and pipeline catalysts (Prelude Therapeutics IND mid-2026) offer spots of alpha. Overall, sparse staples-specific insights suggest sector stability via ETF holdings, but portfolio-level tilt to tech implies rotation risks if staples rally.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 12, 2026

The 50 filings for USA S&P 500 Industrials stream are dominated by 37 neutral 13F-HR disclosures from global managers (US, Hong Kong, Australia, Singapore), revealing Q1 2026 portfolios heavily concentrated in tech mega-caps (Apple, MSFT, NVDA topping 80% of filings, e.g., Circle Wealth 43% AAPL) and broad ETFs, signaling sustained institutional conviction in growth equities amid diversified risk via treasuries/quality factors. Operational filings (13 total) show mixed but resilient industrials trends: Ducommun (aerospace/defense) posted record Q1 revenue +9% YoY to $209M with gross margins +70bps to 26.9% and adj EBITDA +19%; Venture Global (LNG/infra) surged revenue +59% YoY to $4.6B, raising FY26 EBITDA guidance to $8.2-8.5B with new $8.6B project financing. Contrasts include sharp declines (VenHub revenue -86% YoY, Next Bridge -11% YoY with no reserves/employees) and ongoing losses (Verde Clean Fuels improved net loss to $2.4M YoY but cash burn persists; BCSF NII -8% QoQ, NAV -2.2%). Capital allocation leans supportive (BCSF $0.42 dividend covered, Venture $0.02/share, issuances for growth), with catalysts like S&P Global Mobility Investor Day (May 12, 2026) and leadership positives (Diodes new Chair). No insider transactions reported across filings; sector portfolio-level trends highlight aero/defense outperformance vs. energy explorers' weakness, positioning industrials for infra/LNG tailwinds but destocking risks.

7 high priority 43 medium 50 total filings